ADC Therapeutics

Youtube Subscribe

Open: 2.01 Close: 2.12 Change: 0.11

What an AI found about ADC Therapeutics Company Inc after reading the whole Internet.

How much time have you spent trying to decide whether investing in ADC Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about ADC Therapeutics are: …

Concept Map

Semantic Network

Stock Summary

ADC Therapeutics SA develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA is in Phase II clinical trial for the treatment of.

Today's Summary

US-Chinese company Adcentrx Therapeutics has raised $38m in a Series A+ round to begin a phase 1 trial of its lead candidate antibody-drug conjugate.

Today's News

Adcentrx Therapeutics SA (ADCT) Stock Price Today, News, Quotes, FAQs and Fundamentals StockTwits Logo Join the conversation! Build your trading network. Link Your Portfolio and become verified Sign Up Log In Log In. Log in Log In to become verified. Mersana Therapeutics has developed highly differentiated and innovative antibody-drug conjugate (ADC) platforms, with both cytotoxic and immunostimulatory payloads. ADCs are the fastest growing class of oncology therapeutics with an expected global market value of $7.5 billion. US-Chinese company Adcentrx Therapeutics has raised $38m in a Series A+ round to begin a phase 1 trial of its lead candidate antibody-drug conjugate.

Stock Profile

"ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBD–dimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland."

Keywords

Are looking for the most relevant information about ADC Therapeutics? Investor spend a lot of time searching for information to make investment decisions in ADC Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about ADC Therapeutics are: Log, Therapeutics, Adcentrx, become, verified, antibodydrug, conjugate, and the most common words in the summary are: therapeutic, pharmaceutical, pharma, adc, bioscience, biotech, company, . One of the sentences in the summary was: US-Chinese company Adcentrx Therapeutics has raised $38m in a Series A+ round to begin a phase 1 trial of its lead candidate antibody-drug conjugate.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #pharmaceutical #pharma #adc #bioscience #biotech #company.

Read more →

Youtube Subscribe

---